“Not a lot of people are aware that the first ever ex-vivo gene therapy has been approved not in Boston or in Silicon Valley but in Milano thanks to the collaboration between San Raffaele Hospital and a big pharma company. In Italy we are at the frontier of the advanced therapies. Genenta (Nasdaq: GNTA) is now developing the second generation of cell&gene therapies, moving from rare diseases to oncology, and leveraging experience and track record of the Italian leadership in this space.”
The Global Forum on Health Innovation will focus on the potential of science, technology and data and the promotion of their use to build resilient and sustainable health systems.
